Ibraheem Mahmood

Induction Healthcare Group PLC is a leading healthcare technology company that helps healthcare professionals deliver better care more efficiently. The Group has four platforms, Induction Switch and Induction Guidance, that support healthcare professionals in multiple markets, including UK, Ireland, Australia and South Africa; Induction Zesty, a leading provider of patient portals to NHS Hospitals in the UK and Induction Attend Anywhere a comprehensive remote consultation management and delivery platform that allows healthcare organisations running many clinics, each staffed by many providers, to systematically deploy remote consultation capabilities across their entire operation.

AMO Pharma is a biopharmaceutical company incorporated in February of 2015. The co-founder, Dr. Michael Snape, has extensive experience in senior scientific and operational roles in both large pharma and biotech companies spanning more than twenty-five years, and has brought together a targeted and experienced senior management team with a proven track record of success in all phases of product development and acquisition. The company is working to identify and advance promising therapies for the treatment of serious and debilitating diseases in patient populations with significant areas of unmet need, including rare, debilitating childhood onset neurogenetic disorders with limited or no treatment options. AMO-02 is an investigational medicine that has not yet been approved for the treatment of patients anywhere in the world. For more information, please visit the AMO Pharma website at http://www.amo-pharma.com/.

Oxford Science Enterprises (OSE) exists to transform Oxford’s cutting-edge scientific research into companies to tackle the world’s greatest challenges. We strive for global impact and strong investor returns. We’re an independent investment company and venture builder, powered by a unique partnership with the University of Oxford. We have unrivalled access to world-leading science, and a 60+ strong team embedded in Oxford’s innovation ecosystem. Our proven venture-building engine systematically creates 8-10 new companies each year – and this is set to double by 2030. We find. We fund. We build. In our first decade, we’ve created 50+ core companies, partnered with 300+ co-investors, and together invested more than £3bn. And we’re only just getting started – with a new wave of Oxford spinouts emerging and later-stage companies scaling fast. Based in the heart of Oxford, our mission is clear: turning world-class science into transformational companies with global impact and billion-pound potential.

Induction Healthcare Group PLC is a leading healthcare technology company that helps healthcare professionals deliver better care more efficiently. The Group has four platforms, Induction Switch and Induction Guidance, that support healthcare professionals in multiple markets, including UK, Ireland, Australia and South Africa; Induction Zesty, a leading provider of patient portals to NHS Hospitals in the UK and Induction Attend Anywhere a comprehensive remote consultation management and delivery platform that allows healthcare organisations running many clinics, each staffed by many providers, to systematically deploy remote consultation capabilities across their entire operation.

DrugDev, an IQVIA company, is an innovative technology company which provides cloud-based solutions to help sponsors, CROs and investigators do more clinical trials together. Built around the largest global network of active opted-in investigators, DrugDev’s unified solutions suite optimizes site selection and startup, investigator payments and clinical operations. DrugDev also serves as the trusted third-party host of the revolutionary Investigator Databank collaboration and powers the TransCelerate Investigator Registry.

Shire is now part of Takeda. Follow us at https://www.linkedin.com/company/takeda-pharmaceuticals/